AI Article Synopsis
- Andrographolide (Andro) derivatives can affect various enzymes and a new method using nitro group substituted boron dipyrromethene (NBDP) was developed to improve cancer cell absorption and therapeutic effectiveness against breast cancer.
- Two types of NBDP-based compounds, NBDP-Andro and nano NBDPAndro@PEG, were created and examined through spectroscopic techniques, revealing enhanced emission properties and interactions with enzymes like lipase.
- Experiments showed that NBDP-Andro effectively binds with lipase and triggers interactions with proteins, while the MTT assay indicates that nano NBDPAndro@PEG significantly inhibits MCF-7 breast cancer cell proliferation, suggesting its potential as
Article Abstract
Andrographolide (Andro) derivatives can interfere with a variety of enzymes. To increase the cancer cell absorption of Andro and to enhance the therapeutic effect of breast cancer, nitro group substituted boron dipyrromethene (NBDP) was used as the carrier of Andro. Two NBDP based assemblies (NBDP-Andro and nano NBDPAndro@PEG) were synthesized and characterized by spectroscopic methods. The affinity of Andro with NBDP enhanced the emission of NBDP. The interaction of the compounds with lipase was also studied. NBDP-Andro can bind with lipase and form new species with an emission at 360 nm. Results demonstrate that the Andro of NBDP-Andro drives the interaction of compounds with protein (BSA) and lipase by inter-molecular forces. The large red shift emission at 611 nm of the NBDPAndro@PEG is observed and discussed. Also, the MTT assay confirms that Nano NBDPAndro@PEG can enhance the inhibition rate of the proliferation of MCF-7 breast cancer cells. Therefore, nitro substituted BODIPY can be a carrier of andrographolide for cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.saa.2021.120180 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report.
J Cancer Res Ther
December 2024
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Shandong, China.
Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has revolutionized one of the standard most efficient treatments for EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR-TKI, is currently one of most efficient treatments in clinical practice. However, it has a potentially fatal side effect: interstitial lung disease (ILD).
View Article and Find Full Text PDFPolatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.
J Cancer Res Ther
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Background: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.
Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.
Association of diabetes mellitus with long-term prognosis after ablation therapy for patients with hepatocellular carcinoma: A single-center cohort study.
J Cancer Res Ther
December 2024
Department of Ultrasonic Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.
Background: This study investigated the clinical efficacy and prognostic factors of ablative treatment in hepatocellular carcinoma (HCC) patients with and without diabetes mellitus (DM).
Methods: Retrospective data were collected from HCC patients who underwent ablation between January 2016 and December 2019. The baseline clinicopathological characteristics and long-term outcomes, such as overall survival (OS) and recurrence-free survival (RFS), were compared between those with and without DM.
Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimens or chemotherapy: A study based on the SEER database and multicentric real-world settings.
J Cancer Res Ther
December 2024
Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, PR China.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare lung cancer characterized by early metastasis and invasion. It is predominantly diagnosed at a locally advanced or metastatic stage, hindering the possibility of surgical intervention. However, a standard treatment for advanced PSC remains unestablished.
View Article and Find Full Text PDFComparison between lymph and non-lymph node resection in patients with stage IA non-small-cell lung cancer: A retrospective study.
J Cancer Res Ther
December 2024
No. 2 Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Objective: This retrospective study aimed to determine the need for lymph node resection during surgical treatment in patients with stage IA non-small-cell lung cancer (NSCLC).
Materials And Methods: A total of 1428 patients diagnosed with cT1N0M0 1 A stage NSCLC who underwent surgery were divided into two groups: lymphadenectomy (n = 1324) and nonlymphadenectomy (n = 104). The effects of lymph node resection on overall survival (OS) and recurrence-free survival (RFS) and on clinicopathological factors that affected the prognosis of the patients were investigated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!